Harmonic Pharma has developed a unique «pharmacological rediscovery ©» know-how based on polypharmacology to characterize new uses of safe drugs. Our approach allows an accelerated pre-clinical investigation in the newly identified indication while advancing drug candidates to a de-risked clinical development sooner.
Oncology is one of the major priorities of the company.
Michel Souchet, PhD – CEO
Harmonic Pharma is the very first company developing and applying the polypharmacology paradigm to strategic therapeutic areas such as oncology. The company’s know-how derives from a breakthrough innovation allowing to revisit safe drugs and drug candidates.
Harmonic Pharma’s pipeline comprises a selection of drugs with a known safety profile that can be evaluated rapidly in phase IIb, once efficacy in the novel selected indication is demonstrated.
Novacap partnership
5 December 2017
Harmonic Pharma is proud to announce a close collaboration with Novacap, a global player of pharmaceutical synthesis in Europe, Asia and America ! Find all the details of this partnership in the polypharmacology field in this release.
View all newsInvestment key factors:
